<DOC>
	<DOCNO>NCT01702740</DOCNO>
	<brief_summary>The main purpose study evaluate safety pharmacokinetics ( PK , action drug body period time ) multiple intravenous ( IV ) administration CNTO 136 patient cutaneous lupus erythematosus ( CLE ) systemic lupus erythematosus ( SLE ) . The secondary goal study ass pharmacodynamics ( biochemical physiological effect drug mechanism action ) , immune response , clinical response .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics CNTO 136 Patients With Cutaneous Lupus Erythematosus Systemic Lupus Erythematosus</brief_title>
	<detailed_description>In Part A study , patient CLE randomly assign ( like flip coin ) receive multiple IV dose CNTO 136 , human anti-IL 6 monoclonal antibody ( immune protein bind interleukin 6 ) placebo ( substance appear identical treatment active ingredient ) . Patients study personnel know identity administer treatment ( double-blind study ) . Increasing dos give , base safety data collect initial week treatment . In Part B , also double-blind , patient SLE randomly assign receive multiple IV dose high well-tolerated dose , determine Part A , CNTO 136 , placebo .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<criteria>Diagnosis cutaneous lupus erythematosus ( CLE , include subacute cutaneous lupus erythematosus , discoid lupus erythematosus , lupus erythematosus tumidus ) systemic lupus erythematosus ( SLE ) Had body weight le equal 100 kg Patients Part A take systemic medication CLE stable dose 4 week first study agent infusion Patients Part B take systemic medication SLE stable dose least 3 month first study agent infusion Given inform consent willing able adhere study visit schedule protocol requirement ; agree avoid alcohol intake ; take adequate measure prevent pregnancy Significant history concurrent medical condition ( lupus ) Use specific previous concurrent medication investigational therapy Known suspect allergy study agent constituent , recently donate blood , significant laboratory test value require intervention Patients SLE Part B could active central nervous system lupus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Cutaneous lupus erythematosus</keyword>
	<keyword>Systemic lupus erythematosus</keyword>
	<keyword>Lupus erythematosus</keyword>
	<keyword>Human anti-IL 6 monoclonal antibody</keyword>
	<keyword>Sirukumab</keyword>
</DOC>